Decision Algorithm for Switching from Alendronate to Denosumab

Assessment of BMD Response to Guide Treatment Decisions

The American Society of Clinical Oncology recommends continuing alendronate if BMD is stable or improving (T-score >-2.0) with no new fractures and patient has good tolerance to the medication 1, 2
Switch to denosumab when BMD shows continued decline despite adequate alendronate therapy (annual decrease in BMD of ≥4-5% in patients who were osteopenic at baseline) 2
The National Comprehensive Cancer Network suggests switching to denosumab when T-score remains <-2.0 despite bisphosphonate treatment 2
Patients with high fracture risk factors alongside suboptimal BMD response should be considered for denosumab therapy 2

For patients receiving aromatase inhibitors or androgen deprivation therapy, consider switching to denosumab if T-score is <-2.0 or if patient has ≥2 clinical risk factors for fracture 2
Denosumab 60mg every 6 months is the treatment of choice for men on ADT and postmenopausal women with early breast cancer at low risk for disease recurrence 2
In cancer treatment-induced bone loss, denosumab reduced fracture risk by 50% compared to placebo, regardless of baseline BMD 2

When discontinuing denosumab, a bisphosphonate should be initiated to prevent rebound bone loss 3, 4, 5
Patients switching to denosumab should have dental evaluation before initiating therapy 3, 4, 5
Vitamin D deficiency should be corrected with adequate calcium intake throughout denosumab treatment 3, 4, 5
Monitor bone turnover markers at baseline and 3 months after therapy change to assess treatment response 6

Standard denosumab dosing is 60mg subcutaneously every 6 months 2
Denosumab should be administered every 4 weeks in cancer patients with bone metastases; extending intervals beyond this frequency is not recommended 3, 4, 5